Colucid Pharmaceuticals Inc Careers in Durham, NC

CoLucid was founded in 2005 to advance innovative drug candidates with the potential to provide safe and effective treatments for CNS disorders. The company's pipeline includes lasmiditan, a novel treatment for migraine headache, COL-204 for wake promotion, and a conjugated stigmine platform that has generated a series of preclinical candidates for the chronic pain, Alzheimer's disease and psychiatric disorders. Lasmiditan, (COL-144), has been designed to deliver efficacy in migraine without the vasoconstrictor effects of other migraine therapies. It is a member of a novel chemical class called "ditans" which penetrates the central nervous system (CNS) and selectively targets 5-HT1F receptors expressed in the trigeminal nerve pathway. Having received definitive proof of concept of lasmiditan treating acute migraine in Phase 2b trials, CoLucid is designing pivotal trials to further confirm lasmiditan's safety and efficacy prior to submission for approval as well as to allow for its use